Neogenomics, Inc.
NEO
$7.42
$0.294.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.21% | -6.97% | 4.41% | 23.38% | 12.13% |
| Total Depreciation and Amortization | -2.95% | -0.94% | -0.82% | -0.83% | 2.45% |
| Total Amortization of Deferred Charges | 1.38% | 1.39% | 1.25% | 1.25% | 1.40% |
| Total Other Non-Cash Items | 20.58% | 9.45% | 8.68% | 32.30% | 28.61% |
| Change in Net Operating Assets | -7.59% | -211.81% | 84.01% | 141.35% | -233.72% |
| Cash from Operations | 2.27% | -44.89% | 268.20% | 997.42% | -104.18% |
| Capital Expenditure | 19.43% | -64.36% | -152.67% | -74.51% | 43.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.92% | -74.72% | -70.98% | -9.14% | -40.27% |
| Cash from Investing | -75.49% | -131.79% | -116.89% | -51.08% | -38.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.30% | 6.68% | -36.24% | 2,013.98% | -42.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -39.52% | -- | -- | -- |
| Cash from Financing | 16.30% | -45.91% | -36.07% | 2,971.88% | -40.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.88% | -86.15% | -59.76% | 72.08% | -185.08% |